Epidermal Cell Proliferation and Modulation of the Protective Potency of Dexamethasone Against Phorbol Ester-Induced Ornithine Decarboxylase Activity
January 1989
in “
Carcinogenesis
”
Studysummary This study found that dexamethasone treatment inhibited the inflammatory response and the induction of ornithine decarboxylase activity in mouse skin after TPA application, although the effect on ODC was weaker during the hyperplastic stage.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
The study investigated the effects of dexamethasone (DXME) on mouse skin treated with 12-O-tetradecanoyl-phorbol-13-acetate (TPA). DXME, when applied after TPA, inhibited both the dermal inflammatory reaction and the induction of epidermal ornithine decarboxylase (ODC) activity. During the hyperplastic stage, DXME continued to counteract inflammation but only weakly inhibited ODC induction. Interestingly, in DXME-protected skin, the hyperplastic stage was delayed, and TPA strongly induced ODC activity in the epidermal cell layer before this stage. The study suggested that as the proliferation process was induced, epidermal cells became more sensitive to TPA, potentially becoming less reliant on inflammatory factors for ODC induction.
